Sparteine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Sparteine
(−)-Sparteine.svg
Systematic (IUPAC) name
(7α,9α)-sparteine
Clinical data
AHFS/Drugs.com International Drug Names
Legal status
?
Identifiers
CAS number 90-39-1 YesY
ATC code C01BA04
PubChem CID 644020
DrugBank DB06727
ChemSpider 559096 YesY
UNII 298897D62S YesY
KEGG D01041 YesY
ChEBI CHEBI:28827 YesY
ChEMBL CHEMBL44625 N
Synonyms (6R,8S,10R,12S)-7,15-diazatetracyclo[7.7.1.02,7.010,15]heptadecane
Chemical data
Formula C15H26N2 
Mol. mass 234.380 g/mol
Physical data
Density 1.02 g/cm³
Melt. point 30 °C (86 °F)
Boiling point 325 °C (617 °F)
Solubility in water 3.04 mg/mL (20 °C)
 N (what is this?)  (verify)

Sparteine is a class 1a antiarrhythmic agent; a sodium channel blocker. It is an alkaloid and can be extracted from scotch broom. It is the predominant alkaloid in Lupinus mutabilis, and is thought to chelate the bivalents calcium and magnesium. It is not FDA approved for human use as an antiarrhythmic agent, and it is not included in the Vaughn Williams classification of antiarrhythmic drugs.

It is also used as a chiral base in organic chemistry, and as a ligand in organic chemical synthesis.

Biosynthesis[edit]

Sparteine is a lupin alkaloid containing a tetracyclic bis-quinolizidine ring system derived from three C5 chains of lysine, or more specifically, L-lysine.[1] The first intermediate in the biosynthesis is cadaverine, the decarboxylation product of lysine catalyzed by the enzyme lysine decarboxylase (LDC).[2] Three units of cadaverine are used to form the quinolizidine skeleton. The mechanism of formation has been studied enzymatically, as well as with tracer experiments, but the exact route of synthesis still remains unclear.

Tracer studies using 13C-15N-doubly labeled cadaverine have shown three units of cadaverine are incorporated into sparteine and two of the C-N bonds from two of the cadaverine units remain intact.[3] The observations have also been confirmed using 2H NMR labeling experiments.[4]

Enzymatic evidence then showed that the three molecules of cadaverine are transformed to the quinolizidine ring via enzyme bound intermediates, without the generation of any free intermediates. Originally, it was thought that conversion of cadaverine to the corresponding aldehyde, 5-aminopentanal, was catalyzed by the enzyme diamine oxidase.[5] The aldehyde then spontaneously converts to the corresponding Schiff base, Δ1-piperideine. Coupling of two molecules occurs between the two tautomers of Δ1-piperideine in an aldol-type reaction. The imine is then hydrolyzed to the corresponding aldehyde/amine. The primary amine is then oxidized to an aldehyde followed by formation of the imine to yield the quinolizidine ring.[5] The breakdown of this mechanism is shown in figure 1; however, the intermediates, as mentioned before, were not isolated.

Figure 1. Mechanistic Biosynthesis of Sparteine

More recent enzymatic evidence has indicated the presence of 17-oxosparteine synthase (OS), a transaminase enzyme.[6][7][8][9][10][11] The deaminated cadaverine is not released from the enzyme, thus is can be assumed that the enzyme catalyzes the formation of the quinolizidine skeleton in a channeled fashion (Figure 2)., [9][10][11] 7-oxosparteine requires four units of pyruvate as the NH2 acceptors and produces four molecules of alanine (Figure 3). Both lysine decarboxylase and the quinolizidine skeleton-forming enzyme are localized in chloroplasts.[12]

Figure 2.Biosynthesis of sparteine showing proposed ring cyclization steps
Figure 3.Schematic Biosynthesis of Sparteine with OS

See also[edit]

References[edit]

  1. ^ Dewick, P.M. (2009). Medicinal Natural Products, 3rd. Ed. Wiley. p. 311. 
  2. ^ Golebiewski, W.M., Spenser (1988). "Biosynthesis of the lupine alkaloids. II. Sparteine and lupanine". Can. J. Chem. 66 (7): 1734. doi:10.1139/v88-280. 
  3. ^ Rana, J., Robins, D.J. (1983). "Quinolizidine alkaloid biosynthesis: incorporation of [1-amino-15N,1-13C]cadaverine into sparteine". J. Chem. Soc., Chem. Comm. 22: 1335–6. 
  4. ^ Fraser, A.M., Robins, D.J. (1984). J. Chem. Soc., Chem. Comm. 22: 1147–9. 
  5. ^ a b Aniszewski, T. (2007). Alkaloids - Secrets of Life, 1st Ed. Elseview. pp. 98–101. 
  6. ^ Wink, M., Hartmann, T. (1984). Enzymology of Quinolizidine Alkaloid Biosynthesis; Natural Products Chemistry: Zalewski and Skolik (Eds.). pp. 511–520. 
  7. ^ Wink, M. (1987). "Quinolizidine Alkaloids: Biochemistry, Metabolism, and Function in Plants and Cell Suspension Cultures". Plant Medica: 509–514. 
  8. ^ Wink, M., Hartmann, T. (1979). "Cadaverine--pyruvate transamination: the principal step of enzymatic quinolizidine alkaloid biosynthesis in Lupinus polyphyllus cell suspension cultures". FEBS Letters 101 (2): 343–346. doi:10.1016/0014-5793(79)81040-6. PMID 446758. 
  9. ^ a b Perrey, R., Wink, M. (1988). Z. Naturfrosh 43: 363–369. 
  10. ^ a b Atta-ur-Rahman (Ed.) (1995). Natural Products Chemistry 15. Elsevier. p. 537. ISBN 0-444-42691-4. 
  11. ^ a b Roberts, M., Wink, M. (Eds.) (1998). Alkaloids: Biochemistry, Ecology, and Medicinal Applications. Plenum Press. pp. 112–114. 
  12. ^ Wink, M., Hartmann, T. (1980). Z. Naturforsh 35: 93–97.